ABSTRACT
INTRODUCTION
The importance of the immune checkpoint receptor programmed cell death protein 1 (PD-1) and its ligands programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2) in the regulation of immune responses has gained vast scientific interest in the past decade. While this pathway is physiologically indispensable in controlling auto-reactive T cells, it has been demonstrated that tumors and infectious diseases Research Paper www.oncotarget.com can exploit this pathway to suppress the immune system and promote immune escape in favor of their persistence [1, 2] . Interaction of PD-1 expressed on T cells with its ligands results in immune suppression through interference with the physiological T-cell receptor (TCR) signaling pathway [3] . From meta-analyses, we now know that overexpression of surface or soluble PD-L1 in multiple tumor types is mostly associated with a poor prognosis [4] [5] [6] . Providentially, tumor cell PD-L1 expression has been put forward in different malignancies as a predictive biomarker for higher responsiveness to anti-PD-(L)1 therapy [7] [8] [9] . Recent clinical trials, for example in melanoma, have demonstrated a favorable clinical outcome after anti-PD-1 treatment in patients with high PD-L1 expression [10] . These findings have led to large pharmaceutical investments in the investigation and development of antibodies blocking this pathway, directed to either the receptor or its ligands [11] [12] [13] . Success of this approach is illustrated by the growing list of clinical trials implementing anti-PD-(L)1 antibodies (over 500 registered clinical trials) in more than 200 different malignancies on clinicaltrials.gov (April 26th, 2018) and has recently resulted in US FDA and EMA approvals of the anti-PD-1 antibodies nivolumab (BristolMyers Squibb, US) and pembrolizumab (Merck, US) and the anti-PD-L1 antibodies atezolizumab (Genentech, US), avelumab (Merck & Pfizer, US) and durvalumab (Medimmune/AstraZeneca, US).
Evaluation of the bioactivity of PD-1 or PD-L1 blocking antibodies, was performed by a number of research groups [14] [15] [16] [17] . Although their research offers reliable characterization of such antibodies, long-term and laborious experimental protocols and the need for primary cells makes its usage complicated to standardize. The growing need of bioassays to test anti-PD-1/PD-L biologicals like antibodies or other targeted moieties [18] , led to the development and marketing of PD-1/PD-L1 blockade bioassays by a selected number of companies. All current commercially available assays (Amsbio, UK; BPS Bioscience, USA; DiscoverX, USA; Explicyte, France; GenScript, China; Promega, USA) employ bioluminescent luciferase as a nuclear factor of activated T cells (NFAT)-driven reporter gene in the commonly used genetically modified Jurkat T cell line to measure polyclonal TCR-mediated effector T-cell activation. Under normal circumstances, TCR triggering leads to activation of NFAT-proteins and subsequent transcriptional regulation of downstream genes which bear an NFAT-response element (NFAT-RE) in their promoter region [19] . Binding of PD-1 with its ligands disturbs the TCR signaling, resulting in debilitated NFAT activation and downstream NFAT-regulated gene expression [3, 20, 21] . As stimulator, these assays optionally provide stably engineered PD-L1-expressing artificial antigen-presenting cells (aAPCs) to activate the Jurkat cells in an antigen-independent manner. Quantification of TCR activation in the absence versus presence of a PD-1/PD-L-targeted molecule is assessed based on luciferase activity. The high-throughput potential (mostly 96-well plate automated readout) and short-term assay duration (1-day) makes these off-the-shelf bioassays highly valuable in compound screening.
With the rise of cellular immunotherapy approaches, PD-1-targeted (combination) therapies have gained particular interest [22] . These approaches aim at promoting antigen-specific tumor targeting by the immune system while overcoming immune evasion and suppression by the tumor micro-environment [23] . Preclinical data provide evidence of increased T cell activation after combined cellular therapy with PD-1 pathway blockade [24] [25] [26] and a number of clinical trials evaluating the synergistic effect of anti-PD-(L)1 and cellular therapy like dendritic cell (DC) therapy (e.g. NCT01067287, www.clinicaltrials.gov) or adoptive T-cell transfer (NCT02621021), are ongoing. Since none of the currently available PD-1-targeted bioassays provide antigen-specific or multiparametric information, we further expanded the possibilities of these assays by developing a new cellular antigen-specific PD-1-sensitive bioassay with varied readout possibilities. By engineering a genetically modified TCR-deficient Jurkat T cell line, we developed a versatile PD-1-sensitive, multiparametric T cell assay with antigen-specific properties combined with short-term assay duration and high-throughput potential comparable with the already available bioassays. Customizable antigen-specificity through transfection of messenger RNA (mRNA) encoding for the TCR of interest, enables this assay to be employed in various fields of research. This assay not only allows screening of PD-1/PD-L-targeted compounds, but as well allows evaluation of antigen-specific immunogenicity of therapeutics that indirectly target the PD-1 pathway like some cellular therapies (e.g. dendritic cell vaccines [12] . In this context, our assay could accelerate studies on antigenspecific checkpoint-targeted cell interactions and therapies, providing a valuable tool for both translational and clinical research on PD-1-targeted cellular immunotherapy strategies.
RESULTS AND DISCUSSION
Generating off-the-shelf PD-1 + antigen-specific T cell lines
To obtain a readily available PD-1-positive (PD-1 + ) T cell model for assessment of PD-1/PD-L axis involvement in T-cell signaling, the PD-1-negative 2D3 (PD-1 − 2D3) cell line -a derivative of the established Jurkat T cell line characterized by CD8 expression, lack of endogenous TCR and expression of enhanced Green Fluorescent Protein (eGFP) under the control of NFAT promoter -was stably transduced to express surface PD-1 (PD-1 + 2D3; Figure 1 ). The absence of an endogenous TCR allows for reliable introduction of a www.oncotarget.com TCR of interest. Both 2D3 non-transduced and PD-1-transduced 2D3 cells could reproducibly and efficiently be transfected with Wilms' Tumor-1 (WT1) or glycoprotein 100 (gp100) epitope-specific TCR mRNA, using our inhouse developed mRNA electroporation method [27] [28] [29] Figure 1B) . Evaluating its off-the-shelf use, TCR-positive 2D3 cells were aliquoted for cryopreservation and were assessed for viability and stability of PD-1 and TCRαβ surface expression after thawing. As illustrated in the quadrant plots both PD-1 and TCRαβ (87.0 ± 4.3% for PD-1 − 2D3, 88.3 ± 1.4% for PD-1 + 2D3 cells) expression remained − and PD-1 + 2D3 cells were viably recovered (97.7 ± 0.6% and 97.0 ± 0.7%, respectively). Furthermore, these amenable PD-1 − or PD-1 + 2D3 cell lines are easy to maintain in regular culture medium and are not subjected to any enrichment and cytokine-supplemented expansion protocols unlike primary or transduced antigen-specific T cell clones which are laborious and often difficult to maintain in culture [30] . With mRNA electroporation, highly pure TCR-positive T cells can be readily generated, swiftly adaptable to the antigen under investigation, facilitating the development of a variety of PD-1-sensitive antigenspecific T cell models. Our optimized electroporation procedure results in stable expression up to at least 72 hours after electroporation [29] . However, when preferred, stable transduction with a TCR of interest could further simplify the assay protocol to better mimic primary antigen-specific T cell clones, while precluding repetitive mRNA transfections.
Introduced TCR triggers robust antigen-specific T-cell activation
To validate that high TCR surface expression corresponds with antigen-specific functionality, TCR mRNA-electroporated PD-1 − or PD-1 + 2D3 cells were stimulated with the prototypic antigen-presenting T2 cell line, which is negative for PD-L expression and thus serves as a PD-1-independent assay control ( Figure 2 .2%] for the WT1 and gp100 models, respectively (P < 0.001 for all T2 pept+ versus T2 pept-conditions). T2 cells on their own (T2 pept-) elicited low non-specific levels of eGFP (<11.2% for WT1, <14.2% for gp100) comparable to previously described T2-mediated background responses [33, 34] , not significantly different from unstimulated (-) effector cells with a background of < 5% eGFP expression ( Figure 2B , left graph). Comparable data were generated by two independent laboratories for both model antigens, showing low inter-and intra-assay variability, emphasizing assay reproducibility and translatability.
Complementary to single-cell analysis, cell-free supernatant of 24-hour co-cultures was collected. As an alternative accessible low-cost readout, analysis of granzyme B secretion of T2 co-cultures with replicate TCR mRNA electroporations of PD-1 − or PD-1 + 2D3 cells was performed at the same time with ELISA ( Figure 2B 
+ stimulator cells and a T cell activator are mostly provided, sufficient to measure potency and stability of antibodies. Given the generic TCR activation, these assays lack the opportunity to evaluate defined antigen-targeted cellular immunotherapies. We aimed to fill this gap with the TCR + PD-1 + 2D3 bioassay, to evaluate tumor antigen-targeted monocyte-derived DC vaccines, known to express significant levels of PD-L1 and PD-L2 [35, 36] . In the absence of PD-1, specific stimulation of TCR + 2D3 cells with peptide-pulsed DCs resulted in significant WT1-specific (35.3 ± 3.0%) and gp100-specific (47.2 ± 6.5%) eGFP expression (mean Figure 3A) . Activation of PD-1 + 2D3 cells with antigen-targeted DCs resulted in significantly lower eGFP expression for both WT1 (12.7 ± 0.5%) and gp100 (12.8 ± 2.8%) T cell models, corresponding with a 64% and 73% lower signal as compared to the PD-1 − 2D3 cells. Validating the mechanism of action, blocking PD-1-transduced 2D3 cells with anti-PD-1 antibody (pembrolizumab) could fully rescue T cell activation to the levels of PD-1 − 2D3 cells (eGFP expression of 36.0 ± 4.0% for WT1 and 40.7 ± 3.6% for gp100), while there was no effect of the antibody on non-transduced 2D3 cells. PD-L surface expression on DCs has been demonstrated to suppress T cell activity in various malignancies [37, 38] and blockade was shown to enhance T cell functions [39] . In the context of DC-based immunotherapy, it has been suggested that in addition to providing immunostimulatory signals [40] [41] [42] the immunopotency of DC vaccination could be improved by suppressing inhibitory checkpoint pathways [12, 35, 43, 44] . With this versatile bioassay, reproduced in two prototypic tumor antigen models, antigen-specific T cell activating capacity of PD-1-targeted approaches in combination with DC-based therapy can be robustly assessed.
In the search for valuable prognostic and predictive biomarkers, PD-L1 tumor expression has drawn the attention [5, 8] . Ambiguous when it comes to prognosis, its predictive value remains debatable [8] . In this context, the applicability of the immunologic PD-1 + 2D3 assay for assessment of antigen-specific PD-L1 to the inhibitory PD-1-signaling pathway, the exact mechanism remains to be elucidated. The gp100 TCR + PD-1 + 2D3 model assay was tested with MCF-7 breast carcinoma cells that were stably transduced with PD-L1 (> 75% PD-L1 + ). In analogy with the PD-L1 + leukemic cells, stimulation with PD-L1 + peptide-loaded MCF-7 cells resulted in significantly lower eGFP expression (11.9 ± 1.2%) as compared to their non-transduced MCF-7 counterparts (17.8 ± 2.8%; mean ± SEM of 4 replicate experiments, Figure 3C ). Abrogating PD-1 signaling with PD-L1 blocking antibody could completely overcome this tumor-mediated T cell suppression (19.4 ± 2.2%) to the levels of eGFP expression in the absence of PD-L1 (19.0 ± 2.6%), highlighting the relevance of PD-1/PD-L1 checkpoint blockade as an immunotherapeutic modality.
Conclusion and future perspectives
In the development process of antigen-specific immune therapy approaches targeting the inhibitory PD-1/ PD-L pathway, we encountered a lack of availability of robust and user-friendly T-cell bioassays. Therefore, we sought to develop a versatile cellular antigen-specific PD-1-sensitive T-cell assay with comprehensive readout possibilities. The here presented assay is unique because of (i) its straightforward customizable antigen-specificity, (ii) its short-term assaying, (iii) its high-throughput potential and (iv) its readily accessible nature. It enables robust research on combinatorial antigen-specific PD-1-targeted immune therapies. Beyond the PD-1/PD-L1 pathway, a collection of additional immune checkpoints are being assessed, including T cell immunoglobulinand mucin-containing molecule 3 (TIM-3), lymphocyte activation gene 3 protein (LAG-3) and T cell immunoglobulin and ITIM domain (TIGIT) [45] . Looking ahead, the concept of this versatile 2D3 cellular assay could be applied for any immune checkpoint or other targeted molecules of interest, paving the way for swift screening of pathway involvement and of new antigen-specific targeted therapeutics. In this context, a comparable jurkat-based reporter system designed to evaluate activating co-signals rather than checkpoint inhibitors was recently published [46] , confirming the need for robust bioassays for evaluation of TCRtargeted therapy approaches. With the advance feature of stimulating with primary antigen-presenting cells, rather than merely artificial antigen-presenting moieties decorated with a known ligand of the immune checkpoint receptor under investigation, this cellular bioassay permits research on immune checkpoint receptors for which the binding partner(s) is unknown. Hence, antigenspecific TCR immune checkpoint receptor-engineered 2D3 cells could provide a valuable tool to accelerate emerging translational and clinical research on antigenspecific checkpoint-targeted cell interactions and therapy approaches. www.oncotarget.com model (A, B) , 5 µg/mL in gp100 model (A)) or PD-L1 (αPD-L1; C) was added to cells 1 hour prior to co-culture to verify PD-1-mediated signaling, where indicated. (A) PD-1-dependent stimulating capacity of two differently generated peptide-pulsed mature monocyte-derived dendritic cells (WT1 (4 DC donors tested in two independent experiments); gp100 (4 DC donors in four independent experiments)). (B)Impact of induced PD-L1 expression on peptide-pulsed THP-1 leukemic cells on WT1-specific T-cell activation (6 replicate experiments). (C) gp100-specific PD-1 + T cell-activating capacity of peptide-pulsed wild-type or stably transduced PD-L1 + MCF-7 breast carcinoma cells (4 replicate experiments). Data information: in A, the horizontal line represents the median percentage eGFP expression (n = 4).
MATERIALS AND METHODS
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Effector cells
2D3 cells were generated from TCR-deficient Jurkat 76 cells (human acute T cell leukemia) by transduction with a CD8 alpha-E2A-CD8 beta construct (both Jurkat 76 cells and CD8-encoding plasmid were kind gifts of Prof. Hans Stauss, Institute of Immunity and Transplantation, University College London, London, UK) and with a plasmid vector containing the enhanced green fluorescein protein (eGFP) gene under the control of a nuclear factor of activated T-cell (NFAT)-dependent promoter (NFAT-eGFP plasmid [47] was kindly provided by Prof. Takashi Saito, Riken Research Center for Allergy and Immunology, Yokohama, Japan). PD-1 + 2D3 cells were generated by transduction of the 2D3 cell line with a human PD-1 plasmid [48] , at a multiplicity of infection (MOI) of 5, using the protocol described previously to transduce human dendritic cells [49] . The production of lentiviral vectors and their characterization by flow cytometry was performed as previously described in Goyvaerts et al. [50] . Both PD-1 − and PD1 + 2D3 cells were maintained in Roswell Park Memorial Institute 1640 (RPMI) culture medium (Gibco Invitrogen) supplemented with 10% fetal bovine serum (FBS; Gibco Invitrogen).
Stimulator cells
The human lymphoblastic HLA-A * 0201 + -restricted TAP-deficient T2 cell line (kindly provided by Dr Pierre Van der Bruggen; Ludwig Institute for Cancer Research, Brussels, Belgium), routinely used to study T-cell activation, was maintained in Iscove's Modified Dulbecco's Medium (IMDM; Gibco Invitrogen) supplemented with 10% FBS. The human leukemic HLA-A * 0201 + THP-1 cell line (ATCC) was stimulated for 24 hours with 40 ng/mL rhIFN-γ) to induce PD-L1 protein expression and maintained in RPMI culture medium (Gibco Invitrogen) with 10% FBS (Gibco Invitrogen). The HLA-A * 0201 + MCF-7 breast carcinoma cell line (ATCC) was stably transduced with a plasmid encoding human PD-L1 [48] at a MOI of 10 according to the previously described protocol (vide supra) and maintained in RPMI medium supplemented with 10% FBS, 2 mmol/L L-glutamine (Sigma-Aldrich), 100 U/mL penicillin, 100 µg/mL streptomycin (Sigma-Aldrich), 1 mmol/L sodium pyruvate and non-essential amino acids (SigmaAldrich). All cell lines were maintained in logarithmic growth phase at 37° C in a humidified atmosphere supplemented with 5% CO 2 . Peripheral blood mononuclear cell (PBMC) isolation and subsequent monocyte isolation for moDC generation was performed as previously described in Van den Bergh et al. [35] or Tuyaerts et al. [51] , where indicated. 
2D3 cells
The human WT1 37-45 -specific TCR gene was generated as previously described [52] . The human gp100 [280] [281] [282] [283] [284] [285] [286] [287] [288] TCRα and TCRβ vectors were kindly provided by Prof. Niels Schaft (Research group leader of the RNAgroup, Department of Dermatology, Universitätsklinikum Erlangen, Erlangen, German) [53] . mRNA transcripts were generated using an mMessage mMachine T7 in vitro transcription kit (Life Technologies) according to the manufacturer's protocol. WT1 TCR mRNA (1 µg/10 6 cells) or gp100 TCRα and TCRβ mRNA (up to 2,5 µg of each per 10 6 cells) was transfected in PD-1 − 2D3 or PD-1 + 2D3 cells in 200 µL Opti-MEM reduced serum medium without phenol red (Life Technologies) in a 4 mm electroporation cuvette (Cell Projects) using Square Wave settings (500 V, 5 ms, 0 gap, 1 pulse; WT1 TCR mRNA) or a time constant protocol (300 V, 7 ms; gp100 TCR mRNA) of a Gene Pulser Xcell ™ device (Bio-Rad Laboratories). TCR mRNA-electroporated cells were used for co-culture 2-4 hours after transfection or aliquoted in FBS + 10% dimethyl sulfoxide (DMSO) as cryopreservation medium for controlled freezing at −80° C. Viability (flow cytometry, vide infra) and cell count (automated ABX Micros 60 cell counter; Horiba) were measured after electroporation and after thawing in pre-warmed IMDM + 10% FBS. The percentage recovery was calculated by dividing the cell count post electroporation with the cell count prior to electroporation, multiplied by 100. 2D3 or PD-1 + 2D3 effector cells at optimized effectorstimulator ratios of 2:1 (WT1-specific experiments) or 10:1 (gp100-specific experiments) and co-cultured for 24 hours at 37° C, 5% CO 2 (unless specified otherwise).
Co-cultures
Flow cytometry analysis
Viability of TCR mRNA-transfected PD-1 − 2D3 and PD-1 + 2D3 cells was assessed by propidium iodide (PI) staining immediately after transfection and at least 1 hour after thawing of cryopreserved cells. TCR mRNA electroporation efficiency was evaluated 24 hours after transfection (pre-and post-cryopreservation) using a phycoerythrin (PE)-labeled anti-human TCRαβ monoclonal antibody (Miltenyi Biotec). Twenty-four hours after stimulation, PD-1 − and PD-1 + 2D3 TCR activation-mediated eGFP expression was determined on cell pellets after surface staining with anti-human PE or allophycocyanin (APC)-H7-conjugated CD8 (BD), followed by 10-minute incubation with 7-aminoactinomycin D (7-AAD; BD) to distinguish between viable and dead cells. All flow cytometric acquisitions were performed on CytoFLEX (Beckman Coulter) or Fortessa (BD) instruments.
Granzyme B ELISA
Secretion of the cytotoxin granzyme B by PD-1 − and PD-1 + 2D3 cells was determined in 24-hour co-culture supernatant with an enzyme-linked immunosorbent assay (ELISA; R&D) following the manufacturer's instructions and acquired on a Victor 3 multilabel counter (Perkin Elmer). A sample dilution of 1:8 was optimal to fit the standard curve of the kit with a detection limit of 2.4 pg/mL and top standard of 833.3 pg/mL.
Statistical analysis
Flow cytometry data were analyzed using FlowJo software (v10.2, TreeStar Inc). Prism software (v5, GraphPad) was used for graphing and statistical calculations. Data were analyzed using (repeated measures) one-way analysis of variance (ANOVA) followed by Bonferroni's post-hoc test. Results were considered statistically significant when P-value was less than 0.05.
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